Barclays raised its price target on Illumina, which appointed an Eli Lilly executive to its board, while Roche launched a cheaper gene sequencing machine.
2 reports, 1 independent
Updated Jun 30
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Barclays raised its price target on Illumina, which appointed an Eli Lilly executive to its board, while Roche launched a cheaper gene sequencing machine.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Illumina
American company that develops systems for the analysis of genetic variation
-
Eli Lilly and Company
American pharmaceutical company
-
Hoffmann-La Roche
Swiss healthcare company